Export financials
Промомед (PRMD)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Промомед Income Statement 2025-2021 | PRMD
Annual Income Statement Промомед
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
Revenue |
37.6 B | 21.5 B | 15.8 B | 13.5 B | 13.2 B |
General and Administrative Expenses |
7.22 B | 3.95 B | 2.93 B | 3.01 B | 2.46 B |
Operating Expenses |
11.4 B | 7.16 B | 4.41 B | 4.16 B | 3.88 B |
Interest Expense |
4.17 B | 2.9 B | 1.59 B | 740 M | 400 M |
Depreciation And Amortization |
1.4 B | 1.1 B | 1 B | 600 M | 400 M |
EBITDA |
15.3 B | 8.23 B | 6.28 B | 5.95 B | 5.03 B |
EBITDA Ratio |
0.41 | 0.38 | 0.4 | 0.44 | 0.38 |
Operating Income |
13.7 B | 6.9 B | 5.6 B | 5.35 B | 4.62 B |
Operating Income Ratio |
0.36 | 0.32 | 0.35 | 0.4 | 0.35 |
Income Before Tax |
7.04 B | 2.86 B | 2.97 B | 3.97 B | 3.38 B |
Net Income Ratio |
0.19 | 0.13 | 0.19 | 0.29 | 0.26 |
Earnings Per Share, EPS |
33 | 13 | 15 | 19 | - |
EPS Diluted |
33 | 13 | 15 | 19 | - |
Weighted Average Shares Outstanding |
212 M | 212 M | 200 M | 212 M | - |
All numbers in RUB currency
Quarterly Income Statement Промомед
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|
Revenue |
15.6 B | 7.3 B | 24.6 B | 8.52 B | 4.49 B |
General and Administrative Expenses |
4.79 B | - | 4.36 B | 2.86 B | - |
Operating Expenses |
8.67 B | - | 7 B | 4.36 B | - |
Interest Expense |
2.52 B | - | 2.34 B | 1.82 B | - |
Depreciation And Amortization |
800 M | - | 700 M | 700 M | - |
EBITDA |
7.68 B | - | 10.9 B | 4.37 B | - |
EBITDA Ratio |
0.492 | - | 0.443 | 0.513 | - |
Operating Income |
6.95 B | - | 10.2 B | 3.48 B | - |
Operating Income Ratio |
0.446 | - | 0.415 | 0.408 | - |
Net Income Ratio |
0.16 | - | 0.229 | 0.164 | - |
Earnings Per Share, EPS |
11.8 | - | 26.6 | 6.56 | - |
EPS Diluted |
11.8 | - | 26.6 | 6.56 | - |
Weighted Average Shares Outstanding |
212 M | 212 M | 212 M | 212 M | 212 M |
All numbers in RUB currency
The income statement is one of the three key financial reports of a company Промомед (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Biotechnology industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Puma Biotechnology
PBYI
|
$ 9.67 | 1.68 % | $ 484 M | ||
|
Processa Pharmaceuticals
PCSA
|
$ 1.49 | 0.62 % | $ 1.95 M | ||
|
Vaxcyte
PCVX
|
$ 73.82 | 30.7 % | $ 10 B | ||
|
PDS Biotechnology Corporation
PDSB
|
$ 1.2 | 60.32 % | $ 55.7 M | ||
|
Pfizer
PFE
|
$ 27.41 | 0.02 % | $ 156 B | ||
|
Precigen
PGEN
|
$ 7.74 | 4.02 % | $ 2.42 B | ||
|
Pharming Group N.V.
PHAR
|
$ 9.8 | 0.51 % | $ 6.75 B | ||
|
Phathom Pharmaceuticals
PHAT
|
$ 6.7 | 1.77 % | $ 489 M | ||
|
Phio Pharmaceuticals Corp.
PHIO
|
$ 0.99 | 0.6 % | $ 5.92 M | ||
|
Pliant Therapeutics
PLRX
|
$ 1.03 | 0.48 % | $ 63.2 M | ||
|
Protalix BioTherapeutics
PLX
|
$ 2.71 | 0.37 % | $ 213 M | ||
|
PMV Pharmaceuticals
PMVP
|
$ 1.78 | 2.29 % | $ 93.5 M | ||
|
Praxis Precision Medicines
PRAX
|
$ 283.56 | 3.0 % | $ 6.38 B | ||
|
PainReform Ltd.
PRFX
|
$ 0.88 | 0.04 % | $ 570 K | ||
|
Prelude Therapeutics Incorporated
PRLD
|
$ 3.77 | 2.72 % | $ 290 M | ||
|
ProQR Therapeutics N.V.
PRQR
|
$ 1.67 | 2.14 % | $ 176 M | ||
|
Prothena Corporation plc
PRTA
|
$ 8.27 | 0.35 % | $ 445 M | ||
|
PTC Therapeutics
PTCT
|
$ 63.65 | 0.3 % | $ 5.06 B | ||
|
Protagonist Therapeutics
PTGX
|
$ 140.63 | 0.41 % | $ 8.94 B | ||
|
Pulmatrix
PULM
|
$ 1.48 | 0.64 % | $ 5.41 B | ||
|
PolyPid Ltd.
PYPD
|
$ 5.2 | 0.19 % | $ 85 M | ||
|
Repare Therapeutics
RPTX
|
- | - | $ 112 M | ||
|
uniQure N.V.
QURE
|
$ 22.8 | 0.39 % | $ 1.31 B | ||
|
Rocket Pharmaceuticals
RCKT
|
$ 2.61 | 1.95 % | $ 290 M | ||
|
Arcus Biosciences
RCUS
|
$ 24.74 | 1.23 % | $ 2.66 B | ||
|
Regeneron Pharmaceuticals
REGN
|
$ 726.47 | 0.05 % | $ 76 B | ||
|
Replimune Group
REPL
|
$ 13.15 | 0.61 % | $ 1.22 B | ||
|
Rafael Holdings
RFL
|
$ 1.47 | 0.65 % | $ 43.3 M | ||
|
REGENXBIO
RGNX
|
$ 7.76 | 4.44 % | $ 400 M | ||
|
Rigel Pharmaceuticals
RIGL
|
$ 47.79 | 1.36 % | $ 860 M | ||
|
Relay Therapeutics
RLAY
|
$ 19.39 | 2.27 % | $ 3.33 B | ||
|
Avidity Biosciences
RNA
|
$ 7.97 | 1.66 % | $ 1.1 B | ||
|
Royalty Pharma plc
RPRX
|
$ 56.66 | 0.36 % | $ 24.4 B | ||
|
Revolution Medicines
RVMD
|
$ 207.68 | 0.5 % | $ 39.5 B | ||
|
Rhythm Pharmaceuticals
RYTM
|
$ 92.45 | 0.24 % | $ 6.01 B | ||
|
Rezolute
RZLT
|
$ 4.33 | 7.98 % | $ 450 M | ||
|
Sana Biotechnology
SANA
|
$ 2.88 | 1.21 % | $ 729 M | ||
|
Seer
SEER
|
$ 2.33 | 3.56 % | $ 129 M | ||
|
SIGA Technologies
SIGA
|
$ 3.48 | 2.96 % | $ 249 M | ||
|
Sol-Gel Technologies Ltd.
SLGL
|
$ 78.95 | 9.65 % | $ 220 M | ||
|
Silence Therapeutics plc
SLN
|
$ 10.14 | 0.78 % | $ 1.44 B | ||
|
SELLAS Life Sciences Group
SLS
|
$ 11.63 | 3.62 % | $ 1.27 B | ||
|
Summit Therapeutics
SMMT
|
$ 17.27 | 3.07 % | $ 12.9 B | ||
|
Syndax Pharmaceuticals
SNDX
|
$ 17.83 | 1.31 % | $ 1.54 B | ||
|
Soligenix
SNGX
|
$ 0.36 | 0.6 % | $ 1.87 M | ||
|
Sanofi
SNY
|
$ 39.51 | 1.19 % | $ 48.2 B | ||
|
Spruce Biosciences
SPRB
|
$ 45.42 | 2.1 % | $ 34.8 M | ||
|
Spero Therapeutics
SPRO
|
$ 1.16 | 4.13 % | $ 65 M | ||
|
Sarepta Therapeutics
SRPT
|
$ 17.49 | 0.7 % | $ 1.75 B | ||
|
Scholar Rock Holding Corporation
SRRK
|
$ 43.4 | 1.41 % | $ 4.98 B |